Lowest-Rated StocksLowest-RatedNASDAQ:FULC Fulcrum Therapeutics (FULC) Stock Price, News & Analysis $3.62 -0.03 (-0.82%) Closing price 04:00 PM EasternExtended Trading$3.62 0.00 (-0.14%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Fulcrum Therapeutics Stock (NASDAQ:FULC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fulcrum Therapeutics alerts:Sign Up Key Stats Today's Range$3.58▼$3.7850-Day Range$3.14▼$7.2552-Week Range$2.83▼$15.74Volume822,191 shsAverage Volume2.20 million shsMarket Capitalization$241.20 millionP/E RatioN/ADividend YieldN/APrice Target$8.20Consensus RatingReduce Company Overview Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms. Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression. The company’s pipeline combines discovery-stage projects with clinical-stage assets, reflecting its commitment to translating foundational science into potential therapies for underserved genetic disorders. Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum maintains research and development facilities in both Cambridge and the San Francisco Bay Area. The company is led by President and Chief Executive Officer Steven L. Holtzman, whose leadership team includes professionals with extensive experience in drug development, regulatory affairs and commercial strategy. Fulcrum collaborates with patient advocacy groups, academic institutions and contract research organizations to advance its programs and broaden access to promising new treatments. Fulcrum Therapeutics serves a global patient population by pursuing therapies for rare and serious genetic diseases with significant unmet medical need. The company’s integrated approach—combining a deep understanding of epigenetic mechanisms with state-of-the-art drug discovery capabilities—positions it to address complex disorders for which conventional therapeutic strategies have been largely ineffective.AI Generated. May Contain Errors. Read More Fulcrum Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreFULC MarketRank™: Fulcrum Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 276th out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingReduce Consensus RatingFulcrum Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, 1 buy rating, 7 hold ratings, and 4 sell ratings.Upside PotentialFulcrum Therapeutics has a consensus price target of $8.20, representing about 126.5% upside from its current price of $3.62.Amount of Analyst CoverageFulcrum Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Fulcrum Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Fulcrum Therapeutics are expected to grow in the coming year, from ($0.67) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulcrum Therapeutics is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulcrum Therapeutics is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulcrum Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Fulcrum Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.40% of the float of Fulcrum Therapeutics has been sold short.Short Interest Ratio / Days to CoverFulcrum Therapeutics has a short interest ratio ("days to cover") of 1.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fulcrum Therapeutics has recently increased by 16.31%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFulcrum Therapeutics does not currently pay a dividend.Dividend GrowthFulcrum Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News SentimentN/A News SentimentFulcrum Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for FULC on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows2 people have added Fulcrum Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $65,700.00 in company stock.Percentage Held by Insiders7.30% of the stock of Fulcrum Therapeutics is held by insiders.Percentage Held by Institutions89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fulcrum Therapeutics' insider trading history. Receive FULC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FULC Stock News HeadlinesInsider Selling: Fulcrum Therapeutics (NASDAQ:FULC) Director Sells $65,700.00 in StockJuly 1, 2026 | insidertrades.comFulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir ExitJune 27, 2026 | finance.yahoo.comNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried to acquire it outright for $40 billion - the White House blocked the deal on national security grounds. So NVIDIA settled for a 20-year supply deal instead. Its architecture delivers '2-3x performance per watt' by NVIDIA's own admission, and its data-center royalties more than doubled last quarter. Analyst Dylan Jovine - who called Palantir at $7.38 and Rocket Lab at $3.80 - has named it his number-one pick ahead of its July 29th earnings report.July 20 at 1:00 AM | Behind the Markets (Ad)Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPJune 21, 2026 | theglobeandmail.comKaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the FirmJune 20, 2026 | theglobeandmail.comFulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & KorsinskyJune 9, 2026 | prnewswire.comKaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact Kaplan Fox Regarding an Investigation Into Possible Securities Law ViolationsJune 6, 2026 | theglobeandmail.comFulcrum Therapeutics lays off 85% of workforce as it seeks strategic alternativesJune 6, 2026 | bizjournals.comSee More Headlines FULC Stock Analysis - Frequently Asked Questions How have FULC shares performed this year? Fulcrum Therapeutics' stock was trading at $11.31 at the start of the year. Since then, FULC stock has decreased by 68.0% and is now trading at $3.62. How were Fulcrum Therapeutics' earnings last quarter? Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its quarterly earnings data on Monday, April, 27th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.06. Read the conference call transcript. When did Fulcrum Therapeutics IPO? Fulcrum Therapeutics (FULC) raised $76 million in an IPO on Thursday, July 18th 2019. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink served as the underwriters for the IPO. Who are Fulcrum Therapeutics' major shareholders? Fulcrum Therapeutics' top institutional investors include Assenagon Asset Management S.A. (1.25%), Hennion & Walsh Asset Management Inc. (0.35%) and Marquette Asset Management LLC (0.06%). Insiders that own company stock include Ra Capital Management, LP, Robert J Gould, Greg Tourangeau and Alan Ezekowitz. View institutional ownership trends. How do I buy shares of Fulcrum Therapeutics? Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fulcrum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fulcrum Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings4/27/2026Today7/20/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 FULC's financial health is in the Red zone, according to TradeSmith. FULC has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FULC CIK1680581 Webwww.fulcrumtx.com Phone(617) 651-8851FaxN/AEmployees100Year Founded2016Price Target and Rating Average Price Target for Fulcrum Therapeutics$8.20 High Price Target$24.00 Low Price Target$3.00 Potential Upside/Downside+126.5%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-27.80% Return on Assets-26.32% Debt Debt-to-Equity RatioN/A Current Ratio34.33 Quick Ratio34.33 Sales & Book Value Annual Sales$80 million Price / Sales3.02 Cash FlowN/A Price / Cash FlowN/A Book Value$6.45 per share Price / Book0.56Miscellaneous Outstanding Shares66,630,000Free Float61,769,000Market Cap$241.20 million OptionableOptionable Beta3.01 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:FULC) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...Chaikin Analytics | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...Behind the Markets | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredTrump is positioned. Elon lights the fuse.Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new report...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
